高龄女性接受促卵泡激素α刺激前使用黄体期雌二醇预治疗与不预治疗的拮抗剂方案编程比较:一项非劣效性随机对照试验
这项非盲随机对照非劣效性试验纳入324例38-42岁接受体外受精的女性,比较黄体期雌二醇预治疗与不预治疗在促卵泡激素α刺激拮抗剂方案中的取卵数。结果显示,预治疗组取卵数非劣效于不预治疗组,且取卵更多安排在工作日,但刺激时间更长、额外促卵泡激素剂量更高;在AMH<1.2 ng/ml亚组中预治疗组取卵数更多,但累积活产率无显著差异。
要点
- 黄体期雌二醇预治疗组取卵数非劣效于不预治疗组(符合方案人群平均差-0.1个,95%CI -1.5至1.3,P=0.004)。
- 预治疗组取卵在工作日的比例高于不预治疗组(91.9% vs 74.2%,P<0.001)。
- 预治疗组刺激时间更长、额外促卵泡激素剂量更高,但活产率与不预治疗组相似。
核心结论
- 在高龄女性中,黄体期雌二醇预治疗编程拮抗剂方案取卵数非劣效于不预治疗。
- 预治疗似乎有助于将取卵安排在工作日,但取卵数的潜在获益仍需在更大样本中验证。
研究设计与样本
- 非盲随机对照非劣效性试验,2016年至2022年开展,中心计算机随机化并隐藏分配。
- 纳入324例38-42岁接受体外受精的女性,意向治疗人群预治疗组164例、不预治疗组160例。
- 符合方案人群291例,预治疗组147例(平均预治疗天数9.8天,标准差2.6),不预治疗组144例。
主要发现
- 符合方案人群取卵数平均差-0.1个(95%CI -1.5至1.3,P=0.004),意向治疗人群平均差-0.44个(95%CI -1.84至0.97,P=0.014),均证明非劣效。
- 预治疗组取卵在工作日的比例为91.9%,不预治疗组为74.2%(P<0.001)。
- 到达取卵阶段者中,预治疗组刺激时间11.7天(标准差1.7)长于不预治疗组10.8天(标准差1.8),P<0.001;额外促卵泡激素剂量预治疗组1040 IU(标准差548)高于不预治疗组778 IU(标准差504),P<0.001。
- 取卵数(8.4 vs 9.1)、MII卵数(7 vs 7.3)、获得胚胎数(5 vs 5.2)在预治疗组与不预治疗组间无显著差异。
- 新鲜移植活产率预治疗组16.2% vs 不预治疗组18.5%,每患者累积活产率17.7% vs 22.9%,两组相似;AMH<1.2 ng/ml亚组中预治疗组取卵数5.1(标准差3.8)多于不预治疗组3.4(标准差2.7),平均差+1.7个(95%CI 0.2至3.2,P=0.022),但累积活产率无显著差异(15.7% vs 7.3%)。
关键数值与推荐
- 预治疗方案:微粒化雌二醇2 mg每日两次,于月经周期第20-24天开始,持续至月经来潮后的周三,随后周五给予促卵泡激素α。
- 不预治疗组于自然周期第1-3天开始刺激;两组均于刺激第6天开始GnRH拮抗剂,第8天加用促卵泡激素。
- 非劣效界值:取卵数平均差95%CI下限在2个卵母细胞以内,单侧α风险2.5%,P<0.025。
临床怎么用
- 在高龄女性中,黄体期雌二醇预治疗可用于编程拮抗剂方案以便安排取卵在工作日。
- 预治疗组刺激时间更长且额外促卵泡激素剂量更高,临床需权衡安排便利性与用药负担。
- 在AMH<1.2 ng/ml的患者中,预治疗可能增加取卵数,但累积活产率未见显著改善。
局限性
- 38岁以上刺激女性取卵数范围宽,提示两组卵巢衰老阶段差异很大。
- AMH<1.2 ng/ml患者亚组分析的样本量有限。
- 预治疗缺乏安慰剂可能引入偏倚。
- 取卵数潜在获益仍需在更大样本、符合Poseïdon分类卵巢储备下降特征的人群中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does luteal estradiol (E2) pretreatment give a similar number of retrieved oocytes compared to no-pretreatment in advanced-aged women stimulated with corifollitropin alfa in an antagonist protocol? SUMMARY ANSWER: Programming antagonist cycles with luteal E2 gave similar number of retrieved oocytes compared to no-pretreatment in women aged 38-42 years. WHAT IS KNOWN ALREADY: Programming antagonist cycles with luteal E2 pretreatment is a valuable tool to organize the IVF procedure better and is safe without any known impact on cycle outcome. However, variable effects were observed on the number of retrieved oocytes depending on the treated population. In advanced-age women, recruitable follicles tend to decrease in number and to be more heterogeneous in size but it remains unclear if estradiol pretreatment could change the oocyte yield through its negative feed-back effect on FSH intercycle rise. STUDY DESIGN, SIZE, DURATION: This non-blinded randomized controlled non-inferiority trial was conducted between 2016 and 2022 with centrally computerized randomization and concealed allocation. Participants were 324 women aged 38-42 years undergoing IVF treatment. The primary endpoint was the total number of retrieved oocytes. Statistical analysis was performed with one-sided alpha risk of 2.5% and 95% confidence interval (CI) with the non-inferiority of E2 pretreatment proved by a P value <0.025 and a lower delta margin of the CI within two oocytes compared to no pretreatment. Secondary endpoints were duration and total dosage of recombinant FSH, cancellation rate, percentage of oocyte pick-up (OPU) on working days, total number of metaphase II oocytes and obtained embryos, fresh transfer live birth rate, and cumulative live birth rate. PARTICIPANTS/MATERIALS, SETTING, METHODS: This multicentric study enrolled women with regular cycles, weight >50 kg and body mass index <32, IVF cycle 1-2. According to randomization, micronized estradiol 2 mg twice a day was started on days 20-24 and continued until Wednesday beyond the onset of menses followed by administration of corifollitropin alfa on Friday, i.e. stimulation (S)1 or from D1-3 of a natural cycle in unpretreated patients. GnRH antagonist was started at S6 and additional FSH at S8. MAIN RESULTS AND THE ROLE OF CHANCE: Basal characteristics were similar in patients randomized in E2 pretreated (n = 164) and non-pretreated (n = 160) groups (intended to treat (ITT) population). A total of 291 patients started treatment (per protocol (PP) population), 147 in E2 pretreated group with a mean number [SD] of pre-treatment days 9.8 [2.6] and 144 in the non-pretreated group. Despite advanced age, oocyte yields ranged from 0 to 29 in both groups with a median number of 6 retrieved oocytes in accordance with a mean anti-Müllerian hormone (AMH) level above 1.2 ng/ml. We demonstrated the non-inferiority of E2 pretreatment with a mean difference of -0.1 oocyte 95% CI [-1.5; 1.3] P = 0.004 in the PP population and a mean difference of -0.44 oocyte [-1.84; 0.97] P = 0.014 in the ITT population. Oocyte retrieval was more often on working days in E2 pretreated patients (91.9 versus 74.2%, P < 0.001). In patients reaching OPU, the duration of stimulation was statistically significantly longer (11.7 [1.7] versus 10.8 [1.8] days, P < 0.001) and the extra FSH dosage in addition to corifollitropin alfa was statistically significantly higher (1040 [548] versus 778 [504] IU, P < 0.001) in E2 pretreated than non-pretreated patients. We did not observe any significant differences in the number of retrieved oocytes (8.4 [6.1] versus 9.1 [6.0]), in the number of Metaphase 2 oocytes (7 [5.5] versus 7.3 [5.2]) nor in the number of obtained embryos (5 [4.6] versus 5.2 [4.2]) in E2 pretreated patients compared to non-pretreated patients. The live birth rate after fresh transfer (16.2% versus 18.5%, respectively), and the cumulative live birth rate per patient (17.7% versus 22.9%, respectively) were similar in both groups. Among the PP population, 31.6% of patients fulfilled the criteria for group 4 of Poseïdon classification (AMH <1.2 ng/ml and/or antral follicle count <5). In this sub-group of patients, we observed in contrast a statistically higher number of retrieved oocytes in E2 pretreated patients compared to non-pretreated (5.1 [3.8] versus 3.4 [2.7], respectively, the mean difference of +1.7 oocyte [0.2; 3.2] P = 0.022) but without significant difference in the cumulative live birth rate per patient (15.7% versus 7.3%, respectively). LIMITATIONS, REASONS FOR CAUTION: Our stimulated women older than 38 years obtained a wide range of collected oocytes suggesting very different stages of ovarian aging in both groups. E2 pretreatment is more likely to increase oocyte yield at the stage of ovarian aging characterized by asynchrony of a reduced follicular cohort. Another limitation is the sample size in sub-group analysis of patients with AMH <1.2 ng/ml. Finally, the absence of placebo for pretreatment could also introduce possible bias. WIDER IMPLICATIONS OF THE FINDINGS: Programming antagonist cycles with luteal E2 pretreatment seems a useful tool in advanced age women to better schedule oocyte retrievals on working days. However, the potential benefit of the number of collected oocytes remains to be demonstrated in a larger population displaying the characteristics of decreased ovarian reserve encountered in Poseïdon classification. STUDY FUNDING/COMPETING INTEREST(S): Research grant from (MSD) Organon, France. I.C., S.D., B.B., X.M., S.G., and C.J. have no conflict of interest with this study. I.C.D. declares fees as speaker from Merck KGaA, Gedeon Richter, MSD (Organon, France), Ferring, Theramex, and IBSA and participation on advisory board from Merck KGaA. I.C.D. also declares consulting fees, and travel and meeting support from Merck KGaA. N.M. declares grants paid to their institution from MSD (Organon, France); consulting fees from MSD (Organon, France), Ferring, and Merck KGaA; honoraria from Merck KGaA, General Electrics, Genevrier (IBSA Pharma), and Theramex; support for travel and meetings from Theramex, Merck KGaG, and Gedeon Richter; and equipment paid to their institution from Goodlife Pharma. N.C. declares grants from IBSA Pharma, Merck KGaA, Ferring, and Gedeon Richter; support for travel and meetings from IBSA Pharma, Merck KGaG, MSD (Organon, France), Gedeon Richter, and Theramex; and participation on advisory board from Merck KGaA. A.G.L. declares fees as speaker from Merck KGaA, Gedeon Richter, MSD (Organon, France), Ferring, Theramex, and IBSA. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov NCT02884245. TRIAL REGISTRATION DATE: 29 August 2016. DATE OF FIRST PATIENT’S ENROLMENT: 4 November 2016.
引用
- Cédrin-Durnerin I, Carton I, Massin N, et al. Pretreatment with luteal estradiol for programming antagonist cycles compared to no pretreatment in advanced age women stimulated with corifollitropin alfa: a non-inferiority randomized controlled trial. Hum Reprod. 2024. PMID: 39008826. doi:10.1093/humrep/deae167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。